Glenmark Pharmaceuticals receives tentative ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation)
Deepthi | Myequity news | Date : 26-11-2018 10:20:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux-E®1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending September 2018, the Olux-E® Foam, 0.05% market2 achieved annual sales of approximately $13.2 million*.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.